Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Century Therapeutics Inc
(NQ:
IPSC
)
4.270
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
4.270
Bid (Size)
1.710 (2)
Ask (Size)
6.830 (2)
Prev. Close
4.270
Today's Range
4.270 - 4.270
52wk Range
1.280 - 5.510
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Performance
YTD
+17.31%
+17.31%
1 Month
+15.09%
+15.09%
3 Month
+40.46%
+40.46%
6 Month
+111.39%
+111.39%
1 Year
+23.41%
+23.41%
More News
Read More
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 14, 2024
Via
InvestorPlace
Century Therapeutics: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Recap: Century Therapeutics Q3 Earnings
November 09, 2023
Via
Benzinga
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
March 14, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
February 22, 2024
Via
InvestorPlace
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
January 22, 2024
Via
Benzinga
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
December 19, 2023
Via
Benzinga
Topics
ETFs
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
December 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
December 06, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
December 06, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
December 05, 2023
Via
InvestorPlace
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach
November 27, 2023
Via
Benzinga
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
November 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
November 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
November 02, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
September 26, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
August 28, 2023
Via
Benzinga
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results
August 10, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.